Plain-English translation of NCT07812805 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase 1 trial is testing two investigational radiopharmaceuticals: SKL35502, an imaging agent that helps doctors see which tumors have a protein called NTSR1, and , a treatment designed to deliver targeted radiation directly to cancer cells with this protein. Doctors will first use SKL35502 imaging to confirm your tumor has enough NTSR1 present. If it does, you may then receive , the treatment medication, which aims to kill cancer cells while minimizing harm to healthy tissue.
Many advanced cancers have stopped responding to standard treatments. This trial exists because researchers believe targeting a specific protein on cancer cells with precision radiation could offer a new treatment option for patients whose cancers have progressed despite prior therapy.
You likely qualify if…
You likely don't qualify if…
First, you will receive an imaging scan (SKL35502) to confirm your tumor has the target protein NTSR1 and to measure radiation doses your body would receive. If the imaging shows sufficient protein, you will be enrolled and receive injections of , the treatment medication. The trial has two parts: Part A tests different dose levels and gathers safety information, while Part B compares low and high doses, particularly in colorectal cancer patients. You will have regular clinic visits for blood tests, scans, and monitoring, with the exact schedule depending on which part of the study you join.
AI-generated summary from trial data · Sep 11, 2026 · Not medical advice
United States
South Korea